Parathyroid Hormone News
Parathyroid Hormone currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Parathyroid Hormone with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
- Evidence level: L5
- Predicted indications (20):
- migraine disorder (100.0%)
- migraine with brainstem aura (100.0%)
- amenorrhea (disease) (100.0%)
- Raynaud disease (99.8%)
- non-syndromic esophageal malformation (99.8%)
- migraine with or without aura, susceptibility to (99.8%)
- esophageal disease (99.7%)
- atrophoderma vermiculata (99.7%)
- ulerythema ophryogenesis (99.6%)
- erectile dysfunction (disease) (99.1%)
- esophageal ulcer (99.0%)
- sciatic neuropathy (99.0%)
- open-angle glaucoma (98.8%)
- primary hereditary glaucoma (98.7%)
- homozygous familial hypercholesterolemia (98.7%)
- postural orthostatic tachycardia syndrome (98.7%)
- lesion of sciatic nerve (98.6%)
- infectious bovine rhinotracheitis (98.6%)
- malignant catarrh (98.6%)
- antithrombin deficiency type 2 (98.5%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.